Please assess the completion status of the following clinical trial:

Trial Title: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, age greater than or equal to 18 years at the time of signing informed consent~* Body mass index greater than or equal to 30 kg/sqm or greater than or equal to 27 kg/sqm with the presence of at least one of the following weight related comorbidities (treated or untreated): hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease~* History of at least one self-reported unsuccessful dietary effort to lose body weight~Exclusion Criteria:~* Haemoglobin A1c greater than or equal to 48 mmol/mol (6.5%) as measured by central laboratory at screening~* A self-reported change in body weight more than 5 kg (11 lbs) within 90 days before screening irrespective of medical records

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Semaglutide (Type: EXPERIMENTAL): Run-in Period: Participants will receive semaglutide at an escalating doses (0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg) for 20 weeks (week 0 to week 20). The dose will be escalated to next level every 4 weeks.~Maintenance period: Participants will be randomized to receive semaglutide injection for 48 weeks (from week 20 to week 68).~The trial product will be administered as an adjunct to a reduced-calorie diet and increased physical activity during the trial period.
- Placebo (Type: PLACEBO_COMPARATOR): Run-in Period: Participants will receive semaglutide at an escalating doses (0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg) for 20 weeks (week 0 to week 20). The dose will be escalated to next level every 4 weeks.~Maintenance period: Participants will be randomized to receive semaglutide placebo injection for 48 weeks (from week 20 to week 68).~The trial product will be administered as an adjunct to a reduced-calorie diet and increased physical activity during the trial period.

Based on this trial design, predict the completion outcome and termination type (if applicable).